whitepaper
Whitepaper: A guide to achieving better insight with accurate data
In today’s modern world, data is everywhere. This eBook will guide you through the steps of how to achieve more with accurate data.
List view / Grid view
Target Validation
whitepaper
Whitepaper: Opportunities in preclinical development
This whitepaper explains how you can find ways to optimise the holistic preclinical development process...
news
New cancer immunotherapy shows promise in early tests
Researchers report that in preclinical models they can amplify macrophage immune responses against cancer using a self-assembling supramolecule...
news
CLR01 protein found in semen increases the spread of Ebola virus infection
Penn study suggests that targeting amyloid fibrils could prevent sexual transmission...
news
New epigenetic drug against Mantle Cell Lymphoma
A new study presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL)...
article
Streamlining drug discovery assays for cancer and cardiovascular disease
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
article
How the study of lipidomics is benefiting from recent advances in mass spectrometry
There are no short-cuts in the complex field of lipidomics, explains Cristina Legido-Quigley, a Principal Investigator in Systems Medicine at Steno Diabetes Center Copenhagen in Denmark and at King’s College London.
whitepaper
Application note: Simultaneous dual phosphoprotein target analysis with Alpha Terbium SureFire Ultra Multiplex
This application note discusses how the Alpha SureFire® Ultra™ Multiplex technology provides a phosphoprotein multiplexing detection platform that is truly homogeneous and high throughput.
article
Streamlining drug discovery assays for cancer and cardiovascular disease
Declining R&D productivity is a key challenge in the pharmaceutical industry. To increase the success rate of candidate drugs entering the clinical phase, companies must address the early stages of drug discovery.
article
Expert view: Screening tools for better lead characterisation
Predictiveness is one of the key factors for success in the drug discovery workflow. Many compounds fail at late stages due to lack of predictive data or the discovery of unwanted side effects.
news
Controlling ceramides could help treat lipotoxic cardiomyopathy
Study of Drosophila links ceramide accumulation to heart dysfunction...
news
Chondroitin sulphate nets hold promise for heart failure treatments
Researchers discover molecular nets inside heart muscles which hold promise for new heart failure treatment...
news
New to 2018: The role of artificial intelligence in drug discovery
SMi Reports: SMi’s 2nd annual Drug Discovery conference, taking place in London on 21 and 22 March 2018, will discuss the role of artificial intelligence in drug discovery.
webinar
Streamlining drug discovery assays for cancer and cardiovascular disease
1 February 2018 | By PerkinElmer
This webinar discussed a screening assay that recapitulates the activation of ER stress sensor IRE1 and an assay to quantify cell migration phenotypes, as applied to cardiovascular target validation and drug discovery.
webinar
The kinetics of drug binding
15 January 2018 | By BMG Labtech GmbH
Optimising the receptor binding kinetics of new drugs can have significant benefits, ranging from improved duration of action to enhanced efficacy through the insurmountable antagonism of dynamic physiological systems.Despite this, the kinetics of new receptor ligands are rarely measured early in the drug discovery process, largely because current assays are…
